Newsroom Stay up to date with what’s happening at ONO PHARMA USA. Breadcrumb Newsroom Ono Pharmaceutical Co., Ltd. Announced 2022 2Q Financial ResultsCompanyOctober 31, 2022 ONO PHARMA USA continues to expand its organization for enhancement of R&D activities and future commercialization opportunities in the U.S.CompanyAugust 31, 2022 ONO PHARMA USA Initiated Phase 1 Study of ONO-7018, a MALT1 Inhibitor,in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma or Chronic Lymphocytic Leukemia in the U.S.R & DAugust 29, 2022 Ono Pharmaceutical Co., Ltd. Announced 2022 1Q Financial ResultsCompanyAugust 1, 2022 Ono Pharmaceutical Co., Ltd. Announced 2021 Full Year Financial ResultsCompanyMay 11, 2022 Ono Pharmaceutical Co., Ltd. Announced 2021 3Q Financial ResultsCompanyJanuary 31, 2022 Ono Pharmaceutical Co., Ltd. Selected as a Highest Rating A-List Company for Both “Climate Change” and “Water Security” in CDP 2021SustainabilityDecember 15, 2021 ONO Selected for the DJSI World Index and DJSI Asia Pacific Index for Four Straight YearsSustainabilityDecember 12, 2021 Ono Pharmaceutical Co., Ltd. Announced 2021 2Q Financial ResultsCompanyNovember 1, 2021 ONO PHARMA USA Announces Initiation of Phase 1 Study of ONO-4685, an Anti-PD-1/CD3 Bispecific Antibody, in Patients with Relapsed or Refractory T-cell Lymphoma in the U.SR & DOctober 19, 2021 Pagination First page « First Previous page ‹ Page 1 Page 2 Current page 3 Page 4 Next page › Last page Last »
